NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether TransMedics Group, Inc. (“TransMedics Group” or the “Company”) (NASDAQ: TMDX) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.
TransMedics Group operates an organ transplant ecosystem under which it offers patented technology to preserve and mobilize organs, services that support transplant centers and medical teams, and a logistics arm that facilitates the entire chain. On October 28, 2024, the Company released its 3Q24 financial results. During the associated earnings call, the Company revealed that its revenue missed its estimates by a wide margin and that revenues were down sequentially. On this news, the Company’s stock price fell $39.24, or more than 30%, on October 29, 2024, on high trading volume.
What You Can Do – CLICK HERE FOR YOUR OPTIONS AS A SHAREHOLDER
If you purchased or otherwise own TransMedics Group securities and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Nicholas Bruno at (888) 398-9312 or at nbruno@scott-scott.com.
About Scott+Scott
Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.
This may be considered Attorney Advertising.
